



NEWS RELEASE

Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress

2024-05-09

-- Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation --

SEATTLE--(BUSINESS WIRE)--May 9, 2024-- Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been selected for podium presentation. The EHA Congress will be held June 13-16, 2024, in Madrid, Spain. OMS906 is Omeros' investigational inhibitor of MASP-3 targeting the alternative pathway of complement. Two additional poster presentations directed to OMS906 will also be featured at the congress.

The abstracts for all three presentations are scheduled to be published on May 14, 2024 and will be available on the EHA website at eha.web.org. Details of the congress presentations are found below.

OMS906, A Novel Alternative Pathway MASP-3 Inhibitor, Improved Hematologic Parameters in PNH Patients with Suboptimal Response to Ravulizumab Treatment: Phase 2 Dose-Finding Study Interim Results (Abstract #S189)

Session Name: s454 Clinical and translational in bone marrow failure syndromes and PNH

Date: Saturday, June 15, 2024

Podium Presentation Session Time: 4:30 p.m. CEST

Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall N102

Presenting Author: Morag Griffin MBChB, FRCPATH

Clinical Pharmacology of OMS906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract #P834)

Date: Friday, June 14, 2024

Presentation Time: 6:00 p.m. - 7:00 p.m. CEST

Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7

Presenting Author: William Pullman MB BS, PhD, FRACP

Exposure-Response Modeling Using Population PK/PD Methods Reliably Predict Population and Individual Responses of Complement Mature Factor D, Hemoglobin and LDH in PNH Patients Exposed to OMS906 (Abstract #P1920)

Date: Friday, June 14, 2024

Location: IFEMA Madrid Recinto Ferial (Fairgrounds), Hall 7

Presenting Author: William Pullman MB BS, PhD, FRACP

The presentation materials associated with each abstract will be made available on Omeros' website at www.omeros.com following the congress presentations.

About OMS906

OMS906 is an investigational humanized monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system's alternative pathway. The complement system plays a central role in inflammation and becomes activated as a result of tissue damage or microbial infection. Responsible for the conversion of pro-complement factor D to complement factor D, MASP-3 is believed to be the premier target in the alternative pathway – it has the lowest native circulating level and low relative clearance compared to the other alternative pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition leaves intact the lytic arm of the classical pathway, important for fighting infection. Also, unlike other components of the alternative pathway, MASP-3 is believed not to be an acute phase reactant, which could provide a significant advantage to MASP-3 inhibitors, like OMS906, over other alternative pathway inhibitors. MASP-3 inhibitors are thought to have preventive and/or therapeutic effects across a broad range of diseases including paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS), atypical HUS, traumatic brain injury, arthritis, wet age-related macular degeneration, ischemia-reperfusion injury, transplant-related complications and other

immune-related disorders.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 multi-ascending-dose clinical trial. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240509156472/en/): <https://www.businesswire.com/news/home/20240509156472/en/>

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

IR@omeros.com

Source: Omeros Corporation